Emerging second-line treatment approaches in advanced NSCLC: The role of ADCs

touchTALKS for touchONCOLOGY Listen to a leading expert in lung cancer discuss the role of antibody–drug conjugates (ADCs) in the treatment of patients with advanced non-small cell lung cancer, including their structure and mechanistic rationale, the latest clinical trial data and the optimal management of patients receiving ADCs. The expert Dr Rebecca Heist – Massachusetts General Hospital, Boston, MA, USA This touchPODCAST is for HCPs only. This activity is funded by an independent medical education grant from AstraZeneca and is jointly provided by USF Health and touchIME. For further information visit our website: touchoncology.com